Korea's Ministry of Science and ICT named SHIFTBIO an Excellent Corporate R&D Center for the first half of 2026, one of 27 companies nationwide.
We work on drug delivery. Not the drug itself, but the system that carries an already-discovered drug to the exact place it needs to reach. The drugs are good. Getting them across the blood-brain barrier or into inflamed tissue, without hitting healthy cells and again on the next dose, is still the hard part. That is what we do.
The designation does not score a product. It looks at the lab itself, at R&D investment, research staff, and the technology it actually produces. In delivery the cargo keeps changing and the carrier has to be redesigned each time, so the real asset is not any one result but a lab that can keep making them. That is what this confirms.
Korea's Ministry of Science and ICT named SHIFTBIO an Excellent Corporate R&D Center for the first half of 2026, one of 27 companies nationwide.
We work on drug delivery. Not the drug itself, but the system that carries an already-discovered drug to the exact place it needs to reach. The drugs are good. Getting them across the blood-brain barrier or into inflamed tissue, without hitting healthy cells and again on the next dose, is still the hard part. That is what we do.
The designation does not score a product. It looks at the lab itself, at R&D investment, research staff, and the technology it actually produces. In delivery the cargo keeps changing and the carrier has to be redesigned each time, so the real asset is not any one result but a lab that can keep making them. That is what this confirms.